Quantum Genomics raises €11M; Genzyme sees promising results in Cerdelga PhIII;

@FierceBiotech: Can Actavis deliver a promised $6B boost from this pipeline? More | Follow @FierceBiotech

@JohnCFierce: Heard it on the biotech grapevine? Drop me a line. Editor's corner | Follow @JohnCFierce

@DamianFierce: Does anyone know what the "F" in F. Michael Ball stands for? $HSP weirdly won't tell us. | Follow @DamianFierce

> Quantum Genomics raised €11 million in an IPO on the Paris exchange. Release (PDF)

> Sanofi ($SNY) subsidiary Genzyme says its Phase III study of Cerdelga produced promising results for treatment-naive cases of Gaucher disease type 1. Release

> After abandoning plans for an IPO, Dance Biopharm raised $9.5 million in private financing to fund its work on inhalable insulin. More

Medical Device News

@FierceMedDev: ICYMI yesterday: MRI-guided radiation startup files to raise up to $69M in IPO. Article | Follow @FierceMedDev

@VarunSaxena2: FDA agrees to review Pfizer's abuse-deterring opioid candidate. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object. FiercePharmaMarketing article | Follow @EmilyWFierce

> Artificial heart sees most patients to donor heart within a few years. More

> Boston Scientific hands over $600M to settle breach-of-contract Guidant suit with J&J. Article

> Owens & Minor on CEO search ... again. Report

Pharma News

@FiercePharma: Call me Allergan, Actavis says. The buyer will take $AGN's name after their marriage. Release | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Shanghai official linked to $GSK bribery sentenced to 19 years in prison. Article | Follow @CarlyHFierce

> Amphastar pays public agencies rebates after price overdose drug doubles. Story

> Who's the new king of the drug launch hill? Hint: It's all in the Gilead family. Item

> Remicade's U.S. patent rejection could open up early rivalry with Celltrion biosim. Article

> Pharma's top 10 M&A deals of 2014. Special report

Drug Delivery News

> Lupin inks two partnerships to bring lung drugs to overseas markets. Report

> Developer of oral versions of biologic therapies to be purchased by Intrexon. Item

> Actavis divests its drug delivery unit as it barrels toward acquisition of Allergan. News

> Genzyme touts postmarket study of Cerdelga, the only first-line oral therapy for Gaucher disease. Story

> FDA agrees to review Pfizer's abuse-deterring opioid candidate. Article

Diagnostics News

> Lancet study finds that Qiagen's Quantiferon estimates lower rate of TB in China than the traditional test. Story

> Myriad Genetics resolves patent battle with GeneDx over BRCA technology. Item

> Dako joins up with Ono to develop cancer companion Dx. News

> Israel's Pocared receives $15M in funding to commercialize bacteria-identifying computer. Report

> ACT Genomics ropes in $8M for cancer molecular Dx in first private funding round. Article

Pharma Marketing News

> Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object. Story

> Fed-up MD Anderson oncologist jumps on social media to fight drug prices. More

> AstraZeneca picks outspoken (and sometimes critical) prof to join board. Story

> To Pfizer's Chantix, a new JAMA study sounds like 14M potential patients. Article

> AstraZeneca's Pulmicort gets temporary reprieve as judge halts generics launch. Report

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.